NAVI-LARRC: Computer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer

Sponsor
Oslo University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04512937
Collaborator
(none)
20
1
1
84
0.2

Study Details

Study Description

Brief Summary

The aim of this study is to investigate feasibility of computer navigation-assisted surgery in particularly difficult cases of locally advanced (LARC) and recurrent (LRRC) rectal cancer where the standard surgical strategy is expected to result in incomplete tumour removal. The investigators hypothesize that computer navigation-assisted surgery can facilitate improved anatomic orientation in the pelvis enabling tumour removal with free margins in these cases.

Condition or Disease Intervention/Treatment Phase
  • Device: Computer-assisted navigation surgery
N/A

Detailed Description

Curative treatment of rectal cancer requires surgical removal of the tumour. The key challenge in this surgery is to remove the tumour with free margins - R0 resection. Failure to achieve R0 resection often leads to recurrence, which is associated with risk of long-term suffering, poor quality of life and death for the patients. Achieving R0 resection is most difficult in advanced rectal cancer cases, where the tumour is threatening - and sometimes even growing into - neighbouring organs.

Computer navigation-assisted surgery has typically been implemented where extreme surgical precision is necessary or in surgical fields with high anatomic complexity. In such settings, it contributes to preservation of vital anatomic structures close to the tumour, and ensures completeness of resection in cases of malignant disease.

With this in mind, feasibility of navigation in surgically challenging rectal cancer cases will be investigated in this study. If found feasible, navigation could improve surgical management for patients who otherwise would not have the possibility of cure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Computer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2027
Anticipated Study Completion Date :
Sep 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: All patients

All patients will be subjects to the intervention of computer navigation-assisted surgery

Device: Computer-assisted navigation surgery
Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.

Outcome Measures

Primary Outcome Measures

  1. Rate of patients with R0 resection [2 years]

    Resection status will be determined by histopathological examination of specimen

Secondary Outcome Measures

  1. Assessment of whether pre-procedural plan was executed during surgery by comparing pre- and post-operative magnetic resonance imaging (MRI). [2 years]

    Postoperative MRI of the pelvis will be examined and compared to preoperative MRI to evaluate what structures were removed at surgery.

  2. Assessment of whether pre-procedural plan was executed by comparing volume of intended resection with volume of resected specimen. [2 years]

    Volume of intended resection (measured in millilitres) based on pre-procedural MRI will be comparted with volume of resected specimen (measured in millilitres).

  3. Assessment of surgeons' opinion on benefit of computer navigation through qualitative interviews. [2 years]

    Interviews with the surgeons will be semi-structured based on an interview guide. They will be recorded and transcribed, and analyzed using thematic analysis.

  4. Occurrence of 30 day morbidity and mortality assessed with the Accordion severity grading system of surgical complications [30 days after surgery]

    The Accordion severity grading system of surgical complications classifies surgical complications in 6 Levels ranging from mild complications (1) to Death (6)

  5. Assessment of patients quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) [3 years]

    The EORTC QLQ-C30 comprises 30 items (i.e. single questions) registering five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. EORTC QLQ C30 will be completed prior to surgery, and at one and three years after surgery. Changes over time will be analysed.

  6. Overall survival (OS) [5 years]

    OS is defined as time from surgery until death from any cause

  7. Rate of local (re-)recurrence after surgery [5 years]

    Local (re)-recurrence will be determined by routine follow-up

  8. Progression-free survivial (PFS) [5 years]

    PFS is defined as time from surgery until disease progression or death from any cause

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with LARC or LRRC (either biopsy verified, or demonstrated on MRI and confirmed by the MDT decision)

  • The MDT must deem standard surgical strategy at high risk of resulting in R1/R2 resection and computer-assisted navigation likely to improve the chances of obtaining R0 resection.

  • Written informed consent

Exclusion Criteria:
  • Non-adenocarcinoma malignancies.

  • Unresectable distant metastatic disease or unresectable synchronous other malignancy

  • Patients deemed unfit to participation according to the MDT.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oslo University Hospital- The Norwegian Radium Hospital Oslo Norway 0424

Sponsors and Collaborators

  • Oslo University Hospital

Investigators

  • Principal Investigator: Kjersti Flatmark, Professor, Oslo University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kjersti Flatmark, Professor, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT04512937
Other Study ID Numbers:
  • 2020/123753
First Posted:
Aug 14, 2020
Last Update Posted:
Jun 22, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kjersti Flatmark, Professor, Oslo University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 22, 2021